Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma

American Journal of Respiratory Cell and Molecular Biology

Volumn 48, Issue 6, 2013, Pages 685-693

  Yu, Zhi Hua ^a   Xu, Jian Rong ^a   Wang, Yan Xia ^a   Xu, Guang Ni ^a   Xu, Zu Peng ^a   Yang, Kai ^a   Wu, Da Zheng ^b   Cui, Yong Yao ^a   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Airway inflammation; Asthma; Bronchial smooth muscle cells; KCa3.1; Remodeling

Indexed keywords

CALCIUM; CALCIUM ACTIVATED POTASSIUM CHANNEL; MESSENGER RNA; OVALBUMIN; POTASSIUM CHANNEL BLOCKING AGENT; TIARYLMETHANE 34; UNCLASSIFIED DRUG; 1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL STIMULATING AGENT; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA;

AIRWAY REMODELING; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS; CALCIUM CELL LEVEL; CELL CYCLE ARREST; CELL HYPERPLASIA; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GOBLET CELL; HUMAN; HUMAN CELL; HYPERPOLARIZATION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFLAMMATION; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; UPREGULATION; WESTERN BLOTTING; ANIMAL; ASTHMA; BAGG ALBINO MOUSE; CELL MEMBRANE; CELL MOTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; MEMBRANE POTENTIAL; METABOLISM; PATHOLOGY; TH2 CELL;

AIRWAY REMODELING; ANIMALS; ASTHMA; BLOTTING, WESTERN; BRONCHI; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MYOCYTES, SMOOTH MUSCLE; OVALBUMIN; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TH2 CELLS; UP-REGULATION;

MLCS; MLOWN;

EID: 84880979096     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0236OC     Document Type: Article

References (48)

1. Nabe T, Ikedo A, Hosokawa F, Kishima M, Fujii M, Mizutani N, Yoshino S, Ishihara K, Akiba S, Chaplin DD. Regulatory role of antigen-induced interleukin-10, produced by CD4(1) T cells, in airway neutrophilia in a murine model for asthma. Eur J Pharmacol 2012;677: 154-162.
2. Ford AQ, Dasgupta P, Mikhailenko I, Smith EM, Noben-Trauth N, Keegan AD. Adoptive transfer of IL-4Ra1 macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation. BMC Immunol 2012;13:6.
3. Choi JS, Jang AS, Park JS, Park SW, Paik SH, Park JS, Uh ST, Kim YH, Park CS. Role of neutrophils in persistent airway obstruction due to refractory asthma. Respirology 2012;17: 322-329.
4. Schütze N, Lehmann I, Bönisch U, Simon JC, Polte T. Exposure to mycotoxins increases the allergic immune response in a murine asthma model. Am J Respir Crit Care Med 2010;181: 1188-1199.
5. McMillan S, Lloyd C. Prolonged allergen challenge in mice leads to persistent airway remodelling. Clin Exp Allergy 2004;34:497.
6. James AL, Elliot JG, Jones RL, Carroll ML, Mauad T, Bai TR, Abramson MJ, McKay KO, Green FH. Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care Med 2012;185: 1058-1064.
7. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139: 359-370.
8. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006;117: 522-543.
9. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 Step 4 treatment): INNOVATE. Allergy 2005;60: 309-316.
10. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, Brightling CE, Busse WW, Castro M, Dahlen B, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007;119: 1337-1348.
11. Ghanshani S,Wulff H,MillerMJ, Rohm H, Neben A, Gutman GA, Cahalan MD, Chandy KG. Up-regulation of the IKCa1 potassium channel during T-cell activation: molecular mechanism and functional consequences. J Biol Chem 2000;275: 37137-37149.
12. Shumilina E, Lam RS, Wölbing F, Matzner N, Zemtsova IM, Sobiesiak M, Mahmud H, Sausbier U, Biedermann T, Ruth P, et al. Blunted IgE-mediated activation of mast cells in mice lacking the Ca(21)- activated K(1) channel K(Ca)3.1. J Immunol 2008;180: 8040-8047.
13. Puddicombe SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST, Davies DE. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000;14: 1362-1374.
14. Rane SGA. Ca2(1)-activated K1 current in Ras-transformed fibroblasts is absent from nontransformed cells. Am J Physiol Cell Physiol 1991; 260:C104-C112.
15. Shepherd MC, Duffy SM, Harris T, Cruse G, Schuliga M, Brightling CE, Neylon CB, Bradding P, Stewart AG. KCa3.1 Ca21-activated K1 channels regulate human airway smooth muscle proliferation. Am J Respir Cell Mol Biol 2007;37: 525-531.
16. Bradding P, Wulff H. The K1 channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol 2009;157: 1330-1339.
17. Cruse G, Singh SR, Duffy SM, Doe C, Saunders R, Brightling CE, Bradding P. Functional KCa3.1 K1 channels are required for human fibrocyte migration. J Allergy Clin Immunol 2011;128: 1303-1309.
18. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson DL, Das S, Melvin JE, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 2008;118: 3025-3037.
19. Reich EP, Cui L, Yang L, Pugliese-Sivo C, Golovko A, Petro M, Vassileva G, Chu I, Nomeir AA, Zhang LK, et al. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol 2005;35: 1027-1036.
20. Klein H, Garneau L, Trinh NT, Privé A, Dionne F, Goupil E, Thuringer D, Parent L, Brochiero E, Sauvé R. Inhibition of the KCa3.1 channels by AMP-activated protein kinase in human airway epithelial cells. Am J Physiol Cell Physiol 2009;296:C285-C295.
21. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15: 197-204.
22. Si H, Heyken WT,Wölfle SE, Tysiac M, Schubert R, Grgic I, Vilianovich L, Giebing G, Maier T, Gross V, et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca21-activated K1 channel. Circ Res 2006;99: 537-544.
23. Grgic I, Eichler I, Heinau P, Si H, Brakemeier S, Hoyer J, Köhler R. Blockade of the intermediate-conductance Ca21-activated K1 channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2005;25: 704-709.
24. Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H, Wibawa J, et al. Blockade of the intermediateconductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003;108: 1119-1125.
25. Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, Bowles DK. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 2008;28: 1084-1089.
26. McMillan SJ, Xanthou G, Lloyd CM. Therapeutic administration of budesonide ameliorates allergen-induced airway remodeling. Clin Exp Allergy 2005;35: 388-396.
27. Simoes DC, Xanthou G, Petrochilou K, Panoutsakopoulou V, Roussos C, Gratziou C. Osteopontin deficiency protects against airway remodeling and hyperresponsiveness in chronic asthma. Am J Respir Crit Care Med 2009;179: 894-902.
28. Fonseca BP, Olsen PC, Coelho LP, Ferreira TP, Souza HS, Martins MA, Viola JP. NFAT1 transcription factor regulates pulmonary allergic inflammation and airway responsiveness. Am J Respir Cell Mol Biol 2009;40: 66-75.
29. Prieto J, Van Der Ploeg I, Roquet A, Gigliotti D, Dahlén B, Eklund A, Grunewald J. Cytokine mRNA expression in patients with mild allergic asthma following low dose or cumulative dose allergen provocation. Clin Exp Allergy 2001;31: 791-800.
30. Miyazaki E, Nureki S, Fukami T, Shigenaga T, Ando M, Ito K, Ando H, Sugisaki K, Kumamoto T, Tsuda T. Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. Am J Respir Crit Care Med 2002;165: 1125-1131.
31. Rankin JA, Picarella DE, Geba GP, Temann UA, Prasad B, DiCosmo B, Tarallo A, Stripp B, Whitsett J, Flavell RA. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA 1996;93: 7821-7825.
32. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282: 2258-2261.
33. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362: 245-248.
34. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000;165: 108-113.
35. Yoshida T, Ikuta K, Sugaya H, Maki K, Takagi M, Kanazawa H, Sunaga S, Kinashi T, Yoshimura K, Miyazaki J, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 1996;4: 483-494.
36. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004;202: 175-190.
37. Snetkov VA, Hirst SJ, Twort CH, Ward JP. Potassium currents in human freshly isolated bronchial smooth muscle cells. Br J Pharmacol 1995; 115: 1117-1125.
38. Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 2010;3: 385-396.
39. Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, et al. The KCa3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a mouse asthma model. Am J Respir Cell Mol Biol 2013;48: 212-219.
40. Di L, Srivastava S, Zhdanova O, Ding Y, Li Z, Wulff H, Lafaille M, Skolnik EY. Inhibition of the K1 channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci USA 2010;107: 1541-1546.
41. Fioretti B, Castigli E, Micheli MR, Bova R, Sciaccaluga M, Harper A, Franciolini F, Catacuzzeno L. Expression and modulation of the intermediate-conductance Ca21-activated K1 channel in glioblastoma GL-15 cells. Cell Physiol Biochem 2006;18: 47-56.
42. Jäger H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S. Blockage of intermediate-conductance Ca21-activated K1 channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 2004;65: 630-638.
43. Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, Wang YZ. Blockage of intermediate-conductance-Ca21-activated K1 channels inhibits progression of human endometrial cancer. Oncogene 2007;26: 5107-5114.
44. Liu W, Morimoto T, Woda C, Kleyman TR, Satlin LM. Ca21 dependence of flow-stimulated K secretion in the mammalian cortical collecting duct. Am J Physiol Renal Physiol 2007;293:F227-F235.
45. Wonderlin WF, Strobl JS. Potassium channels, proliferation and G1 progression. J Membr Biol 1996;154: 91-107.
46. Begenisich T, Nakamoto T, Ovitt CE, Nehrke K, Brugnara C, Alper SL, Melvin JE. Physiological roles of the intermediate conductance, Ca21-activated potassium channel KCNN4. J Biol Chem 2004;279: 47681-47687.
47. Ohya S, Niwa S, Kojima Y, Sasaki S, Sakuragi M, Kohri K, Imaizumi Y. Intermediate-conductance Ca21-activated K1 channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia. J Pharmacol Exp Ther 2011;338: 528-536.
48. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA- 17043), in patients with sickle cell anemia. Blood 2008;111: 3991-3997.